http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103446087-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56f3f77865ceaebe064e8d9fb1816c5f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 |
| filingDate | 2013-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ea1645519112429a548752301ac8a82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_746a5e17338c95b5c937c510da5f80cd |
| publicationDate | 2013-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103446087-A |
| titleOfInvention | Application of Incarviatone A in endometrial cancer treatment drug |
| abstract | The invention discloses application of Incarviatone A in preparation of an endometrial cancer treatment drug and belongs to the technical field of novel medicine application. Evaluation of in-vitro thiazolyl blue (MTT) anti-tumor activity shows that the Incarviatone A also has remarkable inhabiting effect on growth of human endometrial cancer cell strains ISK and RL95-2. Therefore, the Incarviatone A can be used for preparation of an anti-endometrial cancer drug and has good development and application prospect. The application of the Incarviatone A in the preparation of the endometrial cancer treatment drug is disclosed for the first time. Due to the fact that the fact that the skeleton type is a novel skeleton type, and the high endometrial cancer cell inhibiting activity of the Incarviatone A is previously unimagined. |
| priorityDate | 2013-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447757059 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID64965 |
Total number of triples: 14.